8RRQ

Crystal structure of human SYK in complex with compound 24

This is a non-PDB format compatible entry.

Summary for 8RRQ

• Entry DOI: 10.2210/pdb8rrq/pdb
• Descriptor: Tyrosine-protein kinase SYK, N-[(1S,2R)-2-azanylcyclohexyl]-5-[2-[(3,5-dimethylphenyl)amino]pyrimidin-4-yl]-2-methyl-pyrazole-3-carboxamide, GLYCEROL, ... (4 entities in total)
• Functional Keywords: inhibitor, kinase, transferase
• Biological source: Homo sapiens (human)
• Total number of polymer chains: 1
• Total formula weight: 33379.28

Authors

Canevari, G. (deposition date: 2024-01-23, release date: 2024-04-24)

Primary citation

Cervi, G.,D'Alessio, R.,Bindi, S.,Buffa, L.,Burocchi, A.,Canevari, G.,Modugno, M.,Motto, I.,Saturno, G.,Orsini, P.
Discovery and optimization of 4-pyrazolyl-2-aminopyrimidine derivatives as potent spleen tyrosine kinase (SYK) inhibitors.
Eur.J.Med.Chem., 270:116375-116375, 2024

PubMed Abstract: Spleen tyrosine kinase (Syk) is a key signal transduction mediator of the B cell receptor (BCR) signaling pathway. Abnormal BCR signaling plays a key role in initiation and development of B-cell-derived hematological malignancies, therefore, Syk represents a potential target for inhibiting the BCR signaling resulting in a therapeutic effect in these cancers. Herein, we describe a novel series of SYK inhibitors with 4-(3'-pyrazolyl)-2-amino-pyrimidine scaffold. Extensive study of structure-activity relationships led to the identification of 1 (NMS-0963), a highly potent Syk inhibitor (IC = 3 nM) endowed with high selectivity within a panel of tested kinases and high antiproliferative activity in SYK-dependent BaF3-TEL/SYK cells and in other BCR-dependent hematological tumor cell lines. Additionally, 1 effectively inhibited Syk phosphorylation and downstream signaling mediators of the BCR in treated cells. In in vivo pharmacokinetics studies, 1, displayed good pharmacokinetics properties, with linear exposure with dose and excellent oral bioavailability. These findings suggest that 1 is a promising new Syk inhibitor for treating BCR-dependent hematological cancers.

PubMed: 38604095
DOI: 10.1016/j.ejmech.2024.116375

Experimental method

X-RAY DIFFRACTION (1.6 Å)